4vHPV Type Prevalence Down After Vaccine Introduction

Share this content:
4vHPV Type Prevalence Down After Vaccine Introduction
4vHPV Type Prevalence Down After Vaccine Introduction

TUESDAY, Feb. 23, 2016 (HealthDay News) -- Introduction of the human papillomavirus (HPV) vaccine has correlated with a reduction in quadrivalent HPV (4vHPV) type prevalence among females aged 14 to 19 and 20 to 24 years, according to a study published online Feb. 22 in Pediatrics.

Lauri E. Markowitz, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues analyzed HPV DNA prevalence in cervicovaginal specimens from females aged 14 to 34 years in the National Health and Nutrition Examination Survey for the prevaccine era (2003 to 2006) and four years of the vaccine era (2009 to 2012). They compared the prevalence of 4vHPV types (HPV-6, -11, -16, and -18) and other HPV type categories.

The researchers found that there was a decrease in 4vHPV prevalence between the prevaccine and vaccine eras, from 11.5 to 4.3 percent (adjusted prevalence ratio [aPR], 0.36) and from 18.5 to 12.1 percent (aPR, 0.66) among females aged 14 to 19 and 20 to 24 years, respectively. Older age groups had no decrease in 4vHPV type prevalence. Among sexually active females aged 14 to 24 years, within the vaccine era, 4vHPV type prevalence was lower in vaccinated (one or more dose) versus unvaccinated females (2.1 versus 16.9 percent; aPR, 0.11).

"This finding extends previous observations of population impact in the United States and demonstrates the first national evidence of impact among females in their 20s," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »